52
Participants
Start Date
December 31, 2009
Primary Completion Date
December 31, 2012
Study Completion Date
December 31, 2012
Nilotinib
Participants received two 150 \[a total of 300 mg at each dosing\] mg nilotinib capsules twice daily (bid) orally every morning and every evening approximately 12 hours apart and two 200 mg capsules \[a total of 400 mg at each dosing\] for patients enrolled prior to Protocol Amendment 1).
St. Agnes Hospital, Baltimore
Florida Cancer Institute, New Port Richey
The Jones Clinic, Germantown
St. Francis Hospital and Health Centers IndianaBlood&MarrowTransplantn, Beech Grove
Stroger Cook County Hospital John H. Stroger Hospital, Chicago
St. Louis University Cancer Center, St Louis
Hematology Oncology Services of Arkansas SC, Little Rock
Highlands Oncology Group, Fayetteville
Presbyterian Hospital of Dallas TexasOncology@PresbyterianHosp, Dallas
Texas Oncology Texas Oncology - Sugar Land, Dallas
Texas Oncology, P.A., Bedford
MD Anderson Cancer Center/University of Texas, Houston
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2), San Antonio
USC Norris Cancer Center LAC & USC Medical Center, Los Angeles
Southwest Cancer Care Murrieta, Poway
Northwest Cancer Specialists Salmon Creek Office, Portland
Oregon Health Sciences University, Portland
Rocky Mountain Cancer Centers RMCC - Aurora, Greenwood Village
Cancer Centers of Florida PA Cancer Centers of FL-Orlando-4, Ocoee
Novartis Investigative Site, Brampton
Novartis Investigative Site, Toronto
Novartis Investigative Site, Montreal
Novartis Investigative Site, Montreal
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY